Shots:
- AbbVie has reported topline P-III (M19-044) trial data on Rinvoq (15mg, QD, PO) in pts with non-segmental vitiligo (NSV) who were eligible for systemic therapy
- Trial incl. 2 replicate studies in NSV pts (n=614; ≥12yrs.): Study 1 (206 Rinvoq, 102 PBO) & Study 2 (205 Rinvoq, 101 PBO), where in both studies’ Period A, pts received Rinvoq or PBO for 48wks., followed by Rinvoq for 112wks. in Period B
- Trial met its co-1EP at 48wks. with 19.4% (Study 1) & 21.5% (Study 2) pts achieving T-VASI 50 vs 5.9% for both, plus 25.2% & 23.4% vs 5.9% & 6.9%, respectively, reaching F-VASI 75. For the 2EP of F-VASI 50 at Wk. 48, response rates were 48.1% vs 12.7% in Study 1 & 43.4% vs 12.9% in Study 2
Ref: AbbVie | Image: AbbVie | Press Release
Related News:- AbbVie Reports Topline P-II (ELATE) Trial Data on Botox (OnabotulinumtoxinA) for Upper Limb Essential Tremor
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
